Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users.

de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, den Heeten GJ, van den Brink W.

Brain. 2008 Nov;131(Pt 11):2936-45. doi: 10.1093/brain/awn255. Epub 2008 Oct 7.

2.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
3.

Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.

Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ.

J Psychopharmacol. 2006 Mar;20(2):164-75. Review.

PMID:
16510475
4.

How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?

Kish SJ.

Pharmacol Biochem Behav. 2002 Apr;71(4):845-55. Review.

PMID:
11888575
5.

Neuroimaging research in human MDMA users: a review.

Cowan RL.

Psychopharmacology (Berl). 2007 Jan;189(4):539-56. Epub 2006 Jul 18. Review.

PMID:
16847678
6.
8.

[Chronic neurotoxic damage in ecstasy (MDMA) users. Review of the current state of research].

Gouzoulis-Mayfrank E, Daumann J, Sass H.

Nervenarzt. 2002 May;73(5):405-21. Review. German.

PMID:
12078018
9.

The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.

Gouzoulis-Mayfrank E, Daumann J.

J Psychopharmacol. 2006 Mar;20(2):188-93. Review.

PMID:
16510477
10.
11.

Altered states: the clinical effects of Ecstasy.

Cole JC, Sumnall HR.

Pharmacol Ther. 2003 Apr;98(1):35-58. Review.

PMID:
12667887
12.

Neuroimaging in human immunodeficiency virus infection.

Tucker KA, Robertson KR, Lin W, Smith JK, An H, Chen Y, Aylward SR, Hall CD.

J Neuroimmunol. 2004 Dec;157(1-2):153-62. Review.

PMID:
15579293
13.

Neuroimaging in drug and substance abuse part I: cocaine, cannabis, and ecstasy.

Rojas R, Riascos R, Vargas D, Cuellar H, Borne J.

Top Magn Reson Imaging. 2005 Jun;16(3):231-8. Review.

PMID:
16340647
14.

[Neurotoxicity of the drug Ecstasy. Functional consequences of serotonergic hypoactivity].

de Visme PG.

Ugeskr Laeger. 1998 Oct 12;160(42):6088-91. Review. Danish.

PMID:
9800515
15.

Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.

Parrott AC.

J Psychopharmacol. 2005 Jan;19(1):71-83. Review.

PMID:
15671132
16.

Neuroimaging in bipolar disorder: what have we learned?

Stoll AL, Renshaw PF, Yurgelun-Todd DA, Cohen BM.

Biol Psychiatry. 2000 Sep 15;48(6):505-17. Review. Erratum in: Biol Psychiatry 2001 Jan 1;49(1):80.

PMID:
11018223
17.

Ecstasy: pharmacology and neurotoxicity.

Morton J.

Curr Opin Pharmacol. 2005 Feb;5(1):79-86. Review.

PMID:
15661630
18.

Clinical Application of MR Spectroscopy and Imaging of Brain Tumor.

Morita N, Harada M, Otsuka H, Melhem ER, Nishitani H.

Magn Reson Med Sci. 2010;9(4):167-75. Review.

19.

[Psychiatric and cognitive long-term effects of ecstasy].

Høiseth G, Løvåsdal Ø, Titze TK, Bramness JG, Bachs L.

Tidsskr Nor Laegeforen. 2006 Feb 23;126(5):596-8. Review. Norwegian.

20.

MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.

Clemens KJ, McGregor IS, Hunt GE, Cornish JL.

Drug Alcohol Rev. 2007 Jan;26(1):9-15. Review.

PMID:
17364831
Items per page

Supplemental Content

Write to the Help Desk